- Home
- RDNW vs NBP Comparison
RDNW vs NBP Comparison
Compare RDNW & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RDNW | NBP |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 227.8M | 205.9M |
| IPO Year | 2014 | 2019 |
Fundamental Metrics
Financial Performance| Metric | RDNW | NBP |
|---|---|---|
| Price | $4.93 | $1.26 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $8.50 | ★ $9.00 |
| AVG Volume (30 Days) | 61.8K | ★ 638.2K |
| Earning Date | 11-03-2026 | 08-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.84 | N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $1,793,369,000.00 | N/A |
| Revenue This Year | $3.88 | N/A |
| Revenue Next Year | $5.55 | N/A |
| P/E Ratio | $80.17 | ★ N/A |
| Revenue Growth | ★ 91.10 | N/A |
| 52 Week Low | $3.20 | $1.26 |
| 52 Week High | $8.55 | $5.19 |
Technical Indicators
Market Signals| Indicator | RDNW | NBP |
|---|---|---|
| Relative Strength Index (RSI) | 35.33 | 28.73 |
| Support Level | $4.60 | N/A |
| Resistance Level | $7.14 | $1.44 |
| Average True Range (ATR) | 0.37 | 0.06 |
| MACD | -0.06 | 0.00 |
| Stochastic Oscillator | 15.49 | 16.67 |
Price Performance
Historical ComparisonAbout RDNW RideNow Group Inc.
RideNow Group Inc operates solely as a powersports dealership group. Its offerings include new and pre-owned vehicles such as motorcycles, all-terrain vehicles (ATVs), side-by-side vehicles (SXS), and personal watercraft (PWC). It also sells parts, apparel, and accessories, and provides financing, insurance, and aftermarket products, along with repair and maintenance services. The majority of the company's revenue is derived from powersports vehicle sales, and the rest from parts, service and accessories/merchandise, and finance and insurance products.
About NBP NovaBridge Biosciences American Depositary Shares
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.